Identification of HSP90 inhibitors as a novel class of senolytics.

ABSTRACT: Aging is the main risk factor for many chronic degenerative diseases and cancer. Increased senescent cell burden in various tissues is a major contributor to aging and age-related diseases. Recently, a new class of drugs termed senolytics were demonstrated to extending healthspan, reducing frailty and improving stem cell function in multiple murine models of aging. To identify novel and more optimal senotherapeutic drugs and combinations, we established a senescence associated β-galactosidase assay as a screening platform to rapidly identify drugs that specifically affect senescent cells. We used primary Ercc1 ^-/- murine embryonic fibroblasts with reduced DNA repair capacity, which senesce rapidly if grown at atmospheric oxygen. This platform was used to screen a small library o

SUBMITTER: Fuhrmann-Stroissnigg H 

PROVIDER: S-EPMC5583353 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature